United States Patent 8,163,904: What the Claims Cover, What They Don’t, and Where the Landscape Pushes
United States Patent 8,163,904 protects a single drug substance salt and a narrow crystallization process that yields a hydrated salt form. It also extends to formulations that contain that salt and carrier(s). The claim set is largely centered on 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide in specific hydrochloride salt hydrates and the operational conditions for making it in methanol under nitrogen.
1) What is actually claimed as the protected drug substance?
Salt identity: hydrochloride of a specific benzamide scaffold
Claim 1 defines the salt as:
- 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
- in monohydrochloride form (HCl salt)
In functional terms, claim 1 is not a class claim over salts generally. It is limited to one named active scaffold plus monohydrochloride.
A second claim locks in one specific hydration state
Claim 4 narrows claim 1 further to:
- the monohydrochloride monohydrate
So the patent landscape effect is:
- If a competitor makes the same free base and then forms a different salt or a different hydrate level, the literal coverage does not track claim 1 or 4 cleanly.
- If a competitor makes the same HCl salt but with a different hydration state than “monohydrochloride monohydrate,” claim 4 is the immediate target, and claim 1 may become the fallback depending on whether the resulting material fits “monohydrochloride” and whether the material’s actual composition aligns with the “monohydrate” limitation.
2) How narrow is the synthesis/process protection?
Claim 2 is a crystallization workflow with temperature, atmosphere, and filtration specifics
Claim 2 is a multi-step method claim that recites preparation of:
- 4-methyl-N-[…]-benzamide monohydrochloride monohydrate
Key structural features of claim 2:
Reaction medium and atmosphere
- Combine free base + hydrochloric acid in methanol
- Under a nitrogen atmosphere
- Methanol is repeatedly anchored as the medium, including during rinsing.
Temperature windows that govern how the hydrate form precipitates
The claim fixes a stepwise thermal profile:
- Heat reaction mixture to about 42 to 50 °C
- Stir and filter while maintaining temperature above 40 °C to obtain a “clear solution”
- Cool clear solution to about 30 °C while stirring under nitrogen
- Seed the solution (seed step is explicitly required)
- Cool seeded solution to about 23 °C
- Stir to obtain a suspension
- Cool suspension to about -10 °C
- Stir
- Filter solids
- Rinse solids with cold methanol
- Dry solids at about 50–55 °C and 10–20 torr
What claim 2 effectively locks down
Claim 2 is not just “make the hydrate in general.” It protects a particular sequence:
- nitrogen atmosphere
- methanol medium
- defined temperature ranges
- requirement to filter while warm to get clear solution
- seeding
- precipitation at a deep sub-ambient step (-10 °C)
- cold methanol rinse
- drying conditions (50–55 °C; 10–20 torr)
Process coverage consequence
- A process that uses a different solvent system (not methanol), a different acid source (not HCl), lacks nitrogen, omits seeding, or applies different crystallization temperatures could avoid literal infringement even if it still yields the same end form.
- Conversely, a process that matches the operational profile is structurally aligned to claim 2.
3) Does the patent protect finished drug products?
Claim 3 is a formulation claim tied to claim 1 salt
Claim 3 covers:
- A pharmaceutical composition with:
- therapeutically effective amount of a salt according to claim 1
- at least one pharmaceutically acceptable carrier/diluent/vehicle/excipient
This does not claim broad formulation technology. It ties the drug substance identity to claim 1. If the commercial API is outside claim 1’s definition, claim 3 loses the anchor.
Claim interaction
- Claim 3 is the “composition wrapper.”
- Claims 1 and 4 establish the substance.
- Claim 2 establishes how to make the monohydrochloride monohydrate.
4) Claim-by-claim scope map (literal boundaries)
| Claim |
What is claimed |
Core limitations that drive coverage |
Practical infringement pressure |
| 1 |
Salt of the specified benzamide scaffold as monohydrochloride |
exact scaffold + HCl salt + “monohydrochloride” |
“Salt form match” is decisive |
| 2 |
Method to make monohydrochloride monohydrate |
methanol + nitrogen + specific temperature schedule + warm filtration for “clear solution” + seeding + -10 °C crystallization + cold MeOH rinse + drying (50–55 °C; 10–20 torr) |
high selectivity for manufacturing route |
| 3 |
Pharmaceutical composition |
must contain a salt according to claim 1 + carrier |
substance scope controls |
| 4 |
Salt of the scaffold as monohydrochloride monohydrate |
exact scaffold + HCl + monohydrate level |
hydration state is decisive |
5) What the patent does not cover (by structure of the claims)
Based strictly on the claim text provided:
Not covered: alternative salts
The claims are anchored to hydrochloride (HCl). There is no claim language that sweeps in:
- other mineral salts (e.g., sulfate, hydrobromide)
- organic salts (e.g., tosylate, maleate)
- free base alone
Not covered: generic polymorph or hydrate libraries
While the claims do lock a specific monohydrate form in claim 4 and claim 2, there is no explicit polymorph/hydrate genus claim. The scope appears confined to the stated hydrate status.
Not covered: broad formulation without the tied salt
The formulation claim in claim 3 requires “a salt according to claim 1.” That prevents the claim from covering formulations using the free base or other salt forms.
Not covered: alternative process routes
Claim 2 is process-specific. Different solvent systems, different acid addition strategies, or crystallization profiles could sit outside the literal boundaries.
6) Patent landscape implications for business and R&D
A) The competitive threat is mainly around salt form and manufacturing route
Given the claim architecture:
- The strongest competitive risk comes from competitors who commercialize the same HCl monohydrate and follow a similar methanol/nitrogen/seeded cooling profile.
- Generic competitors typically try to avoid narrow process claims, but formulation claims can still capture if the API is within the salt scope.
B) Likely design-arounds
Using only the logic of the limitations in the claims:
- Use a different counterion salt form (avoid hydrochloride).
- Use the hydrochloride but target a different hydrate state than “monohydrochloride monohydrate” to escape claim 4 and the process claim that is explicitly aimed at the monohydrate.
- For process: change solvent system away from methanol, remove nitrogen atmosphere, change temperature schedule, or remove/alter the seeding and warm filtration sequence to avoid claim 2.
C) How claim 2 influences licensing leverage
Even if a competitor obtains the right salt form via a different manufacturing method, claim 2 creates negotiation leverage in two situations:
- When a contract manufacturer follows a process that matches the claimed thermal and operational steps.
- When process comparability can be used evidentially (e.g., documented batch records show close correspondence to the claim steps).
7) Evidence-based scope check: what the claims anchor chemically
Claim 1 and 4 identify:
- the substituted benzamide scaffold
- the salt type: hydrochloride
- for claim 4: hydration state “monohydrate”
- for claim 1: “monohydrochloride” (hydrochloride count; it does not state “monohydrate”)
Claim 2 then ties the monohydrochloride monohydrate to a defined crystallization protocol.
This means the patent is best understood as a salt-form and crystallization route patent, not a broad drug-substance or broad therapeutic-use patent based on the molecular entity alone.
Key Takeaways
- US 8,163,904 protects a specific hydrochloride salt of a single defined benzamide scaffold (claim 1) and a specific hydrate state (claim 4): monohydrochloride monohydrate.
- Claim 2 provides narrow, operationally specific process protection: methanol, nitrogen, stepwise temperature ranges including 42–50 °C, cooling to 30 °C and 23 °C, crystallization at -10 °C, seeding, warm filtration for a clear solution, cold methanol rinse, and drying at 50–55 °C / 10–20 torr.
- Claim 3 covers pharmaceutical compositions only to the extent they contain a salt within claim 1.
- Landscape risk concentrates on competitors who make and supply the same HCl monohydrate and/or who manufacture using a similar methanol/nitrogen seeded cooling and filtration sequence.
FAQs
1) Does the patent protect the free base?
No. The claims provided are directed to hydrochloride salt forms (claim 1 and 4) and to a composition containing the claim 1 salt (claim 3), plus a process that yields the monohydrochloride monohydrate (claim 2).
2) Is the formulation claim broad enough to cover any hydrate?
No. Claim 3 is limited to “a salt according to claim 1.” Without claim 1’s salt identity being present, claim 3 does not apply on its face.
3) How critical is the seeding step in claim 2?
It is explicit and therefore central. Claim 2 includes a required “seeding the solution” step before cooling to about 23 °C and subsequent suspension formation.
4) If a competitor makes the same monohydrochloride monohydrate using a different solvent, is claim 2 avoided?
By claim language, it likely is. Claim 2 specifically requires methanol for combining free base and HCl and includes cold methanol rinsing, so a non-methanol route would not match the recited steps.
5) Does claim 4 add coverage beyond claim 1?
Yes. Claim 4 narrows claim 1 to the monohydrochloride monohydrate form, adding the hydration state limitation.
References
- United States Patent 8,163,904 (claims text as provided in prompt).
